Bile acid distributions, sex-specificity, and prognosis in colorectal cancer

Table 3 Multivariable Cox regression associating 17 bile acid abundances or ratios to 5-year recurrence-free survival (RFS) for patients ≥ 55 years old (n = 197) adjusting for age, sex, tumor anatomic location, stage, and chemotherapy use

Bile acid/ratio	HR	CI95	P value
CA	0.65	0.23–1.80	0.405
GCA	2.16	0.55–8.49	0.269
DCA	0.52	0.16–1.66	0.270
LCA	2.47	0.89–6.83	0.083
UDCA	0.75	0.25–2.27	0.616
TDCA	1.26	0.30–5.25	0.750
TLCA	2.23	0.78–6.41	0.136
GDCA	0.42	0.08–2.36	0.326
TCA/CA	0.79	0.22–2.86	0.724
TCDCA/CDCA	0.4	0.12–1.30	0.127
GCA/CA	3.22	0.71–14.53	0.128
GCDCA/CDCA	3.61	1.10–11.84	0.034
TDCA/DCA	0.92	0.25–3.39	0.896
TLCA/LCA	1.82	0.54–6.13	0.332
GDCA/DCA	0.43	0.10–1.84	0.257
GLCA/LCA	0.55	0.22–1.39	0.207
GUDCA/UDCA	0.62	0.20–1.86	0.392

HR hazard ratio, CI confidence interval, CA cholic acid, CDCA chenodeoxycholic acid, TCA taurocholic acid, TCDCA taurochenodeoxycholic acid, GCA glycocholic acid, GCDCA glycochenodeoxycholic acid, DCA deoxycholic acid, LCA lithocholic acid, UDCA ursodeoxycholic acid, TDCA taurodeoxycholic acid, TLCA taurolithocholic acid, GDCA glycodeoxycholic acid, GLCA glycolithocholic acid, GUDCA glycoursodeoxycholic acid

ISSN: 2042-6410